Roman M J, Alderman M H, Pickering T G, Pini R, Keating J O, Sealey J E, Devereux R B
Department of Medicine, The New York Hospital-Cornell Medical Center, New York 10021, USA.
Am J Hypertens. 1998 Apr;11(4 Pt 1):387-96. doi: 10.1016/s0895-7061(97)00492-5.
Diuretic-based therapy is less effective in reducing the cardiac complications of hypertension than the risk of stroke and may be less effective in reducing left ventricular (LV) mass than is therapy with angiotensin converting enzyme (ACE) inhibition. In view of the strong association of LV hypertrophy with cardiovascular risk, this study was designed to compare the impact of therapy with a diuretic and ACE inhibition on cardiac and vascular structure. Fifty essential hypertensives (74% male, 88% nonwhite) participated in a double-blind study for 6 months and were randomized to either ramipril or hydrochlorothiazide (HCTZ). Echocardiography, carotid ultrasonography, and ambulatory blood pressure (BP) monitoring were performed at baseline and 3 and 6 months after initiation of therapy. The 22 ramipril patients were comparable to the 28 HCTZ patients at baseline in age, race, and 24-h BP. Although HCTZ resulted in a greater reduction in 24-h BP, only treatment with ramipril resulted in a decrease in LV mass (193 to 179 g, P < .005, v 184 to 182 g, P = NS), attributable to a reduction in wall thicknesses but not in chamber diameter. In multivariate analysis, both change in BP and treatment group were independent predictors of change in LV mass. Importantly, although neither drug reduced carotid artery cross-sectional area, relative wall thickness increased due to a tendency for vessel diameter to decrease and wall thickness to increase, particularly in the diuretic group. Ramipril caused a sustained fall in plasma angiotensin II, whereas HCTZ increased angiotensin II levels. Although diuretic therapy was more effective in lowering ambulatory BP in this predominantly nonwhite population, only therapy with ACE inhibition was associated with regression of LV mass. Vascular geometry was altered consistent with the reduction in distending pressure resulting in vascular remodelling.
与降低中风风险相比,基于利尿剂的疗法在降低高血压心脏并发症方面效果较差,并且在减轻左心室(LV)质量方面可能不如血管紧张素转换酶(ACE)抑制疗法有效。鉴于LV肥厚与心血管风险密切相关,本研究旨在比较利尿剂疗法和ACE抑制疗法对心脏和血管结构的影响。五十名原发性高血压患者(74%为男性,88%为非白人)参与了一项为期6个月的双盲研究,并被随机分为雷米普利组或氢氯噻嗪(HCTZ)组。在基线以及治疗开始后3个月和6个月时进行了超声心动图、颈动脉超声检查和动态血压(BP)监测。22名雷米普利患者与28名HCTZ患者在基线时的年龄、种族和24小时血压方面具有可比性。尽管HCTZ导致24小时血压有更大幅度的降低,但只有雷米普利治疗导致LV质量下降(从193克降至179克,P <.005,相比之下,184克降至182克,P =无显著性差异),这归因于壁厚度的减少而非腔直径的减小。在多变量分析中,血压变化和治疗组都是LV质量变化的独立预测因素。重要的是,尽管两种药物都没有降低颈动脉横截面积,但由于血管直径有减小趋势且壁厚度增加,相对壁厚度增加,特别是在利尿剂组。雷米普利导致血浆血管紧张素II持续下降,而HCTZ则升高了血管紧张素II水平。尽管在这个以非白人为主的人群中,利尿剂疗法在降低动态血压方面更有效,但只有ACE抑制疗法与LV质量的消退相关。血管几何形状的改变与扩张压力的降低一致,导致血管重塑。